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Abstract
Hypertension is associated with accelerated bone loss and the renin-angiotensin-aldosterone 
system is a key regulator of blood pressure. Although components of this system are expressed in 
human bone cells, studies in humans are sparse. Thus, we studied the association of circulating 
renin and aldosterone with osteocalcin and bone mineral density. We recruited 373 African 
ancestry family members without regard to health status from 6 probands (mean family size: 62; 
relative pairs: 1687). Participants underwent a clinical exam, dual energy x-ray absorptiometry, 
and quantitative computed tomography scans. Renin activity, aldosterone concentration, and 
osteocalcin were measured in fasting blood samples. Aldosterone to renin ratio was calculated as 
aldosterone concentration/renin activity. All models were analyzed using pedigree-based variance 
components methods. Full models included adjustment for age, sex, body composition, co-
morbidities, lifestyle factors, blood pressure, and antihypertensive medication. Higher renin 
activity was significantly associated with lower total osteocalcin and with higher trabecular bone 
mineral density (both p<0.01). There were also significant genetic correlations between renin 
activity and whole body bone mineral density. There were no associations with aldosterone 
concentration in any model and results for aldosterone to renin ratio were similar to those for renin 
activity. This is the first study to report a significant association between renin activity and a 
marker of bone turnover and bone mineral density in generally healthy individuals. Also, there is 
evidence for significant genetic pleiotropy and, thus, there may be a shared biologic mechanism 
underlying both the renin-angiotensin-aldosterone system and bone metabolism that is 
independent of hypertension.
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INTRODUCTION
The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure and fluid 
balance. The RAAS is a major contributor to essential hypertension and inhibitors of this 
system are some of the most common treatments for hypertension. Hypertension, or high 
blood pressure, has been associated with osteoporosis and low bone mass in some studies1–4. 
Components of the RAAS are expressed in human bone cells5 and can activate a local 
RAAS response that leads to increased bone turnover and decreased bone density1. Indeed, 
there is also evidence for shared genetic determinants of the RAAS and bone mineral density 
(BMD)6.
Research on the RAAS and bone metabolism in humans has focused on patients with 
primary aldosteronism (PA)7–9 or on the effect of RAAS inhibitor therapies on bone10–15. 
The majority of studies on the effect of angiotensin converting enzyme (ACE) inhibitors or 
angiotensin II receptor blockers (ARB) on bone, including those in humans10–13 and animal 
models16–18, suggest that pharmacologic inhibition of the RAAS pathway can lead to 
decreased fracture risk and increased bone mass. However, some studies in humans have 
found the opposite association14, 15. There have only been two studies, each with less than 
50 participants, which examined the association of circulating RAAS measures with BMD 
in humans19, 20. Both studies found that renin activity was directly correlated with BMD, 
although it is unclear if the results are not be generalizable to healthy cohorts because they 
were conducted in highly selected samples of hemodialysis patients20 or premenopausal 
women19. Therefore, in the current study, we aimed to expand on these previous studies by 
using a larger family study of generally healthy men and women in order to further assess 
the association of circulating RAAS measures, including plasma renin activity, plasma 
aldosterone concentration and the aldosterone to renin ratio, with indices of bone turnover 
and BMD. The family study design also allowed us to estimate heritability of these traits and 
to determine if there may be shared genetic determinants underlying these traits.
METHODS
Study Sample
Participants for this analysis were from the Tobago Family Health Study21. Briefly, 8 
individual probands were identified and recruited for the study without regard to their 
medical history on the Caribbean island of Tobago21. Each proband was eligible if they had 
a spouse willing to participate and had at least six living offspring and/or siblings aged ≥18 
years and who were residing in Tobago. All first-, second-, and third-degree relatives of the 
probands and their spouses were invited to participate. Participants had extensive clinical 
exams, medical history interviews and bone mineral density assessment. The current 
analysis includes data on 373 individuals recruited from 6 large families (mean family size = 
62; relative pairs: 1687) who have complete data on osteocalcin (OC), BMD, and RAAS 
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measures, which include plasma renin activity (PRA), plasma aldosterone concentration 
(PAC) and aldosterone to renin ratio (ARR). Written informed consent was obtained from 
each participant. The study was approved by the Tobago Division of Health and Social 
Services and the University of Pittsburgh Institutional Review Boards. All procedures 
followed the principles of the Declaration of Helsinki and were in accordance of institutional 
guidelines.
Blood Sample Assays
Plasma and serum samples were collected on all individuals in the morning after 8+ hours of 
fasting and then frozen at −80°C at time of collection until analysis. The PRA (ng/mL/h) 
was measured using a Clinical Assays GammaCoat radioimmunoassay kit (Baxter 
Healthcare, Cambridge, MA). The PAC (ng/dL) was measured by radioimmunoassay with 
antiserum from Diagnostic Products Corp. (Los Angeles, CA). The ARR (ng/dL per 
ng/mL/h) was calculated as PAC/PRA.
Serum concentrations of total OC were measured, in duplicate, in previously unthawed 
specimens by radioimmunoassay, as previously described elsewhere22. Briefly, OC is 
measured in serum using a radioimmunoassay utilizing an antibody made against OC 
purified from human bone. This antibody recognizes both carboxylated and uncarboxylated 
OC equivalently. Intra-assay variation was 4.8% for total OC. Serum creatinine was 
quantitatively determined by the VITROS CREA Slide method. The Modification of Diet in 
Renal Disease Study formula was used to estimate glomerular filtration rate as: GFR [mL · 
min−1 · (1.73 m2) −1] = 175 × (serum creatinine [mg/dL] −1.154× age [years] −0.203[× 0.742, 
if female] [× 1.212, because they are all of African ancestry]23.
Bone Mineral Density Measures
Integral areal BMD at the proximal femur were measured by dual energy X-ray 
absorptiometry (DXA) using a Hologic QDR-4500W densitometer (Hologic Inc., Bedford, 
MA). The short-term in vivo precision of the DXA measurements for 12 subjects were all 
≤1.16%. Trabecular and cortical volumetric BMD at the left tibia was measured by 
peripheral quantitative computed tomography (pQCT) using an XCT-2000 scanner (Stratec 
Medizintechnik, Pforzheim, Germany). A single axial slice of 2.5 mm thickness with a voxel 
size of 0.5 mm and a speed of 20 mm/s was taken at 33% (cortical) and 4% (trabecular) of 
the tibia length sites. Image processing was performed using the Stratec software package 
(Version 5.5E). The short-term in vivo precision of the pQCT measurements for 15 subjects 
ranged from 0.65% (cortical BMD) to 2.1% (trabecular BMD).
Covariates
Demographic, lifestyle and medical history variables were collected by trained clinic staff 
through administration of a questionnaire and interview. Blood pressure was measured while 
seated three times throughout the visit. The average of the 2nd and 3rd readings for systolic 
and diastolic blood pressures are used in this analysis. Thirty-six participants were on 
antihypertensive medication including 7 on ACE inhibitors, 6 on thiazide diuretics, 5 on 
methyldopa, 2 on calcium channel blockers, 1 on a beta-blocker, 4 on combination therapy, 
and 11 reported being on antihypertensive medication but did not bring it to the clinic visit. 
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Diabetes was defined as a fasting glucose level ≥126 mg/dl or current use of diabetes 
medication24. Smoking status was classified as either current or not (yes/no). Participants 
reporting ever smoking <100 cigarettes in their lifetime were considered non-smokers. 
Alcohol consumption was assessed by questionnaire and was defined as having ≥3 drink per 
week (yes/no) as there was a very low prevalence of substantial alcohol intake. Physical 
activity was dichotomized “active” or “not active” after asking participants if they had 
walked for exercise at all in the past week.
Statistical Analysis
Trait distributions were assessed and, if necessary, transformed by natural logrithms to 
reduce non-normality. Outliers, defined as ≥4 SD from the mean, were removed for each 
trait to reduce undue influence, and no more than 2 observations were removed from any 
trait. Means with standard deviations and medians with interquartile range were calculated 
for normal and non-normal traits, respectively. All analyses of mean differences between 
men and women were tested using the variance components framework implemented in the 
Sequential Oligogenic Linkage Analysis Routines (SOLAR) program25 that accounts for 
complex familial relationships. SOLAR not only controls for this correlated structure, but 
also estimates the proportion of the trait variation that is attributable to genetic, covariate and 
error effects.
To determine the association of RAAS measures with OC and BMD, we calculated the 
percent difference in OC or BMD per 1 SD increased RAAS measure [(calculated as RAAS 
measure beta coefficient/mean OC or BMD)*100%]. These analyses were first done without 
covariates (unadjusted model). Next, we incorporated major determinants of bone (base 
model) including age, sex, height and body weight. Finally, in order to account for all 
potential confounding of these relationships, we added additional parameters (multivariable 
model) for menopausal status, systolic blood pressure, diastolic blood pressure, hypertensive 
medication, eGFR, diabetes, current smoking, drinking, walking and calcium 
supplementation.
To assess the potential shared genetic covariance between RAAS and bone measures, we 
estimated the residual heritability (h2r) and genetic correlations (ρG) in SOLAR25. All 
heritability and genetic correlations were estimated while simultaneously incorporating all 
multivariable covariates used in the full, multivariable model. We first estimated the residual 
heritability (that is, the genetic heritability estimated after removing known covariate effects) 
and next determined the extent of genetic correlation between the variance components of 
PRA and ARR, and OC and BMD measures25, 26. The statistical significance of ρG ≠ 0 was 
tested by a likelihood ratio test of models in which the parameter was or was not 
constrained.
RESULTS
Study Characteristics
The mean age across family members was 42 years with a range of 18–86 years; 62% were 
females (Table 1). Based on mean BMI, participants were overweight and women were more 
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overweight than men (P<0.0001). Women also had a higher prevalence of antihypertensive 
medication use compared to men (12.6% vs. 4.9%; p=0.01), although men had higher 
systolic blood pressure (p=0.01). Compared to men, women had lower kidney function as 
assessed by eGFR (p=0.04) and a higher prevalence of type II diabetes (p=0.03). However, 
men were more likely to have poorer lifestyle habits including current smoking, drinking ≥3 
alcoholic beverages a week and use of calcium supplementation. Women had greater PAC 
(p=0.01) than men but similar PRA and ARR (Table 2). Although OC was similar between 
men and women, women had lower whole body, total hip and trabecular BMD than men 
(p<0.0001 for all).
Association of RAAS Measures with Osteocalcin and Bone Mineral Density
Higher PRA was associated with lower total OC in unadjusted, minimally adjusted and fully 
adjusted models (Table 3). Specifically, in fully adjusted multivariable models, a 1 SD 
increase in PRA was associated with 8% lower total OC (p<0.0001). Additionally, 1SD 
greater ARR was associated with ~10% higher total OC (p<0.0001; Table S1). PRA was not 
associated with whole body, total hip or cortical BMD in any model (Table 3; p>0.05 for 
all). However, PRA was associated with trabecular BMD in all models. We found that a 1 
SD greater PRA was associated with 1.6% greater trabecular BMD in fully adjusted models 
(p=0.01). Similarly, A 1 SD greater ARR was associated with 1.7% lower trabecular BMD 
(p=0.01), but was not associated with other BMD measures (Table S1). There was also no 
evidence of a statistically significant interaction effect of PRA or ARR on BMD or OC by 
hypertension status (all interaction P>0.1; data not show). There was no significant 
association of PAC concentrations with OC or BMD (Table S1).
Genetic Correlations of RAAS Measures with Osteocalcin and BMD
PRA, ARR, OC and BMD measures were each significantly heritable (Tables 4 and S2). 
PRA had a significant, negative genetic correlation with whole body BMD (ρG=−0.40; 
p=0.02), while ARR had significant, positive genetic correlation with total OC (ρG=0.32; 
p=0.02; Table S2). Since there were no significant phenotypic associations of PAC with OC 
or BMD, we did not perform further genetic correlation analyses for these measures.
DISCUSSION
We found that higher PRA or lower ARR, but not PAC, was associated with higher 
trabecular BMD and lower OC in African ancestry families. In addition to these phenotypic 
associations, this is the first study to report significant genetic pleiotropy between RAAS 
measures and indices of bone health. We assessed and controlled for potential confounding 
factors in our analyses and all results were independent of hypertension and its treatment, 
demographic characteristics, co-morbidities and lifestyle factors. Taken together, these 
findings suggest that RAAS measures and bone metabolism may be physiologically linked 
independent of blood pressure and hypertension.
Two existing studies19, 20 reported a direct correlation between PRA and BMD, which is 
consistent with our findings. These findings in humans are also consistent with observations 
in a mouse model1. Ours is the first study to examine the possible relationship between 
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RAAS measures and cortical and trabecular bone in humans. We found that the association 
of PRA with BMD appears to be specific for trabecular bone, which has also been suggested 
by mouse models of osteoporosis27, 28. We saw similar results, though in the expected 
opposite direction (as PRA increases, ARR decreases), for ARR. This suggests that both 
renin activity and the relative levels of renin to aldosterone may be important for skeletal 
health, though aldosterone alone does not appear to be a significant factor.
In order to further evaluate the relationship of RAAS measures with bone, we assessed 
whether there was an association with OC, a major protein component of bone matrix that is 
released into the circulation during bone turnover29. Thus, higher serum OC is associated 
with more bone turnover and, generally, lower BMD29. While there are no previous reports 
of a link between RAAS measures and OC in humans, glucocorticoid activation of the 
RAAS in trabecular bone increases circulating OC and osteoporosis risk in rabbits28. Our 
results show that PRA and ARR are much more strongly associated with circulating OC 
levels than BMD and in a direction consistent with the BMD findings. Therefore, we 
hypothesize that renin may have a primary effect on OC, which in turn leads to secondary 
effects on BMD. Additional studies will be needed to test this hypothesis more directly.
Individuals with primary aldosteronism (PA), a major source of secondary hypertension, 
have lower BMD than controls7–9. While we had no individuals with PA in our study, we 
found no significant association between normal PAC and measures of bone metabolism. 
However, we did find significant associations of the ARR, which is a marker of PA, with OC 
and BMD measures. Greater ARR was associated with lower BMD, consistent with studies 
in PA patients7–9. We also found that greater ARR was significantly associated with greater 
OC (p<0.0001), and there was significant genetic pleiotropy underlying these measures. Our 
findings raise the possibility that BMD may only be affected at clinically high levels of 
aldosterone and/or when RAAS pathway homeostasis is disrupted.
The potential mechanisms underlying these associations are not clear, but it appears that at 
least part of the association is due to shared genetic determinants. The significant genetic 
correlation between PRA and ARR with OC and BMD suggests that some of the genetic 
variation that impacts RAAS measures, also influences bone metabolism. These findings 
replicates results from a broader study of genetic correlation throughout the human genome, 
which found evidence of shared genetic determinants between RAAS measures and BMD6. 
However, there is also evidence that there is a direct interaction of these circulating factors in 
the skeletal environment. In model organisms, local activation of the RAAS on bone cells 
activates angiotensin 2 receptors expressed in osteoblasts1. This activation leads to increased 
osteoclastogenesis and bone turnover, and, thus, to lower bone mass1, 27, 28. This 
mechanistic work in animals is further strengthened by studies that show inhibition of the 
RAAS pathway using ACE inhibitors or angiotensin II receptor blockers leads to decreased 
fracture risk and increased bone mass in humans10–13, 16–18. The findings of the current 
paper are consistent with these previous conclusions, and extend them in a larger study of 
healthy adults who were recruited without regard to hypertension or skeletal health status.
While we had the ability to assess many potential confounders including lifestyle habits, co-
morbidities and hypertension, there remain several potential study limitations. First, we did 
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not have data on dietary intake of vitamin K, which may be an important confounder as it is 
a co-factor required for carboxylation of OC30. However, since our study uses total OC 
level, not only carboxylated OC, we do not believe vitamin K would have a major effect on 
our findings. Our study was relatively small and cross-sectional by design, which limits 
determination of temporality or causality. Additionally, this study was conducted in African 
ancestry families, which limits generalizability to other racial/ethnic or geographic groups. 
Our study also lacks measurement of the full array of RAAS pathway components including 
ACE, angiotensin or angiotensinogen and, therefore, there may be additional factors of the 
RAAS pathway that may be missed by these analyses. However, this study is the first to test 
for an association between any RAAS measures and OC and it is larger than the two 
previous studies of the association of circulating RAAS and BMD in humans14, 15. In 
addition, it is the first study conducted in a sample recruited without regard to health status 
and may, therefore, be more generalizable to a broader population of healthy adults.
PERSPECTIVES
This is currently the largest study of the association between serum biomarkers of the RAAS 
pathway and BMD. It is also the first study to extend the analyses to bone turnover markers, 
be skeletal compartment specific, and to investigate the potential for shared genetic 
determinants underlying these relationships. In a sample of African ancestry families, we 
have identified significant associations between higher PRA (or lower ARR) and higher 
trabecular BMD and lower OC, independent of hypertension. We have also presented the 
first evidence that shared genetic determinants may underlie these associations. Therefore, 
variation in the RAAS pathway due to pharmacological and/or physiological means may 
have previously unrecognized effects on bone metabolism that need to be identified. It is 
also possible that existing therapeutics that alter the RAAS pathway could be useful to 
maintain or improve skeletal health. Future studies will be needed to replicate these results 
in additional populations and to evaluate the mechanisms linking RAAS and bone 
metabolism, including identifying potential shared genetic pathways.
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NOVELTY AND SIGNIFICANCE
1. What is New? This is the largest study to test for an association of circulating 
RAAS measures with measures of bone mineral density. It is also the first in 
African ancestry individuals, the first to also include information on bone 
turnover markers, and the first to test for shared genetic determinants underlying 
these traits.
2. What is Relevant? The association of plasma renin activity and aldosterone to 
renin ratio, and bone mineral density seems to be restricted to trabecular bone. 
They are also strongly associated with osteocalcin, a marker of bone turnover. 
Also, these associations show evidence of having some shared genetic 
determination (pleioptropy).
3. Summary: We found that circulating RAAS measures were associated with 
greater bone mineral density and lower bone turnover independent of the 
confounding effect of hypertension. Additionally, there is evidence that there are 
shared genetic pathways underlying these associations. Lastly, we found no 
association of serum aldosterone concentration with bone in African ancestry 
individuals.
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Table 1
Characteristics of the African Ancestry Families
Characteristic Overall
(N=373)
Men
(N=143)
Women
(N=230)
P-value
Age (years) 42.3±16.8 41.6±17.2 42.7±16.6 0.714
Female (%) 61.7 N/A N/A N/A
Post-Menopausal (%) 19.4 N/A 31.7 N/A
Height (cm) 170.6±8.6 177.4±7.2 166.4±6.5 <0.001
Weight (kg) 82.2±18.9 84.0±17.4 81.1±19.5 0.122
BMI (kg/m2) 28.3±6.4 26.6±5.0 29.3±6.9 <0.001
Systolic Blood Pressure (mmHg) 121.5±24.0 126.1±20.3 118.6±25.6 0.012
Diastolic Blood Pressure (mmHg) 75.2±13.0 76.7±12.5 74.3±13.2 0.157
Antihypertensive Medication (%) 9.7 4.9 12.6 0.010
eGFR (ml/min/1.73 m2) 104.3±27.0 107.1±23.1 102.5±29.0 0.043
Diabetes (%) 15.1 10.6 18.0 0.034
Current Smoking (%) 4.6 11.9 0.0 <0.001
≥3 Alcoholic drinks/week (%) 11.3 26.6 1.8 <0.001
Walk for exercise in past week (%) 69.9 70.6 69.4 0.806
Taking Calcium Supplement (%) 19.6 9.1 26.1 <0.001
Values are presented as mean±SD or %, as appropriate.
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Table 2
Means and standard deviations of RAAS, Bone Mineral Density and Osteocalcin Measures in African 
Ancestry Families
Variable Overall
(N=373)
Men
(N=143)
Women
(N=230)
P-value
Plasma Renin Activity (ng/mL/h)* 3.0 (1.0–6.2) 2.9 (0.9–5.6) 3.1 (1.1–6.5) 0.721
Plasma Aldosterone Concentration (ng/dL)* 9.0 (5.6–13.4) 8.5 (5.4–11.7) 9.5 (5.7–15.2) 0.014
Aldosterone to Renin Ratio (ng/dL per ng/mL/h)* 3.1 (1.3–8.3) 3.2 (1.3–8.1) 3.0 (1.3–8.5) 0.613
Total OC (ug/l) 4.50±2.81 4.59±2.85 4.45±2.79 0.396
Whole Body BMD (g/cm2) 1.19±0.13 1.26±0.11 1.15±0.12 <0.001
Total Hip BMD (g/cm2) 1.11±0.17 1.19±0.14 1.06±0.17 <0.001
Cortical BMD (g/cm3) 1182±30 1181±25 1184±22 0.418
Trabecular BMD (g/cm3) 251±36 264±35 243±34 <0.001
*Renin and aldosterone are displayed as median(interquartile range) due to non-normality
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Table 3
Association of Plasma Renin Activity with Serum Osteocalcin and Bone Mineral Density in African Ancestry 
Families
Bone Measure Model Difference (%) in bone measure per 1 SD PRA* P-value
Total Osteocalcin
(ug/l)
Unadjusted −6.27 <0.0001
Base† −6.90 <0.0001
Multivariable‡ −8.26 <0.0001
Whole Body BMD
(g/cm2)
Unadjusted −0.15   0.803
Base† 0.25   0.617
Multivariable‡ 0.51   0.301
Total Hip BMD
(g/cm2)
Unadjusted 0.59   0.462
Base† 1.19   0.067
Multivariable‡ 1.19   0.070
Cortical BMD
(g/cm3)
Unadjusted −0.11   0.445
Base† −0.17   0.195
Multivariable‡ −0.14   0.244
Trabecular BMD
(g/cm3)
Unadjusted 1.78   0.020
Base† 1.94   0.003
Multivariable‡ 1.61   0.012
*Values shown are the percent difference in bone measure per 1 SD (4.5 ng/mL/h) greater plasma renin activity.
†Base model includes adjustment for age, sex, height and weight.
‡Multivariable model includes adjustment for age, sex, height, weight, menopausal status, systolic blood pressure, diastolic blood pressure, 
hypertensive medication, eGFR, diabetes, current smoking, drinking, walking and calcium supplementation.
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Table 4
Multivariable* Adjusted Genetic Correlations of Plasma Renin Activity with Osteocalcin and Bone Mineral 
Density
Bone Measure Heritability Plasma Renin Activity (H2r ± SE = 0.515 ± 0.10)
(H2r ± SE) ρG ρG P-value
Total OC (ug/l) 0.727 ± 0.11 −0.230 0.148
Whole Body BMD (g/cm2) 0.623 ± 0.12 −0.394 0.023
Total Hip BMD (g/cm2) 0.696 ± 0.10 −0.051 0.755
Cortical BMD (g/cm3) 0.444 ± 0.12 −0.266 0.148
Trabecular BMD (g/cm3) 0.622 ± 0.11 −0.266 0.139
*Multivariable models include adjustment for age, sex, height, weight, menopausal status, systolic blood pressure, diastolic blood pressure, 
hypertensive medication, eGFR, diabetes, current smoking, drinking, walking and calcium supplementation.
H2r: residual genetic heritability estimate after adjustment; ρG estimated genetic bivariate correlation.
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